Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-20 inclisiran study in children aged 6 to under 12 years with heterozygous familial hypercholesterolemia
MOH_2025-02-04_013890Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Inclisiran in Part 1 with Placebo in Part 1 (2 arms). Planned start Feb 2025; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on MOH_2025-02-04_013890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-04_013890.